NewTimeSpace News:As of 13:37 on March 6, 2026, the CSI Innovative Drug Industry Index (931152) surged 2.86%. Among its constituent stocks, Rongchang Biosciences rose 10.66%, Chipharma Biosciences gained 7.51%, and Sinocell Biomedicine advanced 6.93%. Haisco Pharmaceutical, Salubris Pharmaceuticals and other individual stocks followed the upward trend. TheGF CSI Innovative Drugs Industry ETF (515120) rose 2.74% to a latest price of RMB 0.6. Over a longer timeframe, as of March 5, 2026, the ETF had a cumulative increase of 9.38% in the past year, ranking 3rd among 7 comparable funds in terms of growth rate. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

In terms of liquidity, theGF CSI Innovative Drugs Industry ETF posted an intraday turnover rate of 2.98% with a trading volume of RMB 254 million. As of March 5, its average daily trading volume reached RMB 273 million in the past week, ranking top 2 among comparable funds.

In terms of scale, the ETF’s scale has increased by RMB 4.466 billion in the past year, achieving a significant growth, and the newly added scale ranks 1st among 7 comparable funds. (Data source: Wind)

In terms of shares, the ETF’s shares have increased by 62 million in the past week with a remarkable growth, and the newly added shares rank 2nd among 7 comparable funds. (Data source: Wind)

In terms of capital flow, the latest net capital outflow of theGF CSI Innovative Drugs Industry ETF stood at RMB 4.0812 million. Over a longer period, there were net capital inflows on 3 out of the past 5 trading days, with a total inflow of RMB 42.9438 million and an average daily net inflow of RMB 8.5888 million. (Data source: Wind)

Data showed that leveraged funds have been continuously building positions in the ETF. The net margin purchase of theGF CSI Innovative Drugs Industry ETF on the previous trading day reached RMB 5.0413 million, with the latest margin balance at RMB 348 million. (Data source: Wind)

As of March 5, the net asset value (NAV) of theGF CSI Innovative Drugs Industry ETF has risen 5.91% in the past two years. In terms of profitability, as of March 5, 2026, since its establishment, the ETF has achieved a maximum monthly return of 23.00%, a longest streak of five consecutive monthly gains with a cumulative increase of 32.68% during the period, and an average return of 5.63% in rising months. As of March 5, 2026, the ETF had an annualized excess return of 0.81% over the benchmark in the past two years.

In terms of drawdown, as of March 5, 2026, the ETF had a relative benchmark drawdown of 0.05% since the start of the year, with a relatively low drawdown risk among comparable funds.

In terms of fees, the ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%.

In terms of tracking accuracy, as of March 5, 2026, the ETF posted a tracking error of 0.010% in the past three months, ranking the highest in tracking accuracy among comparable funds.

In terms of valuation, the latest price-to-earnings ratio (PE-TTM) of the CSI Innovative Drug Industry Index tracked by the ETF is only 46.57 times, at the 9.51% quantile of the past year. That is, the valuation is lower than that in more than 90.49% of the time in the past year, standing at a historically low level.

TheGF CSI Innovative Drugs Industry ETF closely tracks the CSI Innovative Drug Industry Index. The index selects no more than 50 most representative listed company securities engaged in innovative drug R&D as its constituent samples to reflect the overall performance of listed company securities in the innovative drug industry.

Data showed that as of February 27, 2026, the top 10 weight stocks of the CSI Innovative Drug Industry Index (931152) were WuXi AppTec, Hengrui Medicine, Kelun Pharmaceutical, Fosun Pharma, Huadong Medicine, Changchun High-tech, Tigermed, Pharmaron, BeiGene and Salubris Pharmaceuticals, accounting for a total of 46.43% of the index weight. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

SWSC stated that the total BD contract value in the first two months of 2026 has exceeded USD 50 billion, close to 40% of the full-year 2025 figure, and the upfront payment has surpassed USD 3 billion, accounting for more than 40% of that in 2025. The fundamentals of the innovative drug sector remain sound.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.